A Phase 1 Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

NCT ID: NCT02470286

Last Updated: 2022-03-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-29
• Study Completion Date: 2015-09-30

Brief Summary

The purpose of this phase1 study is to investigate the pharmacokinetics, safety and tolerability of a single oral dose of SA001 and its active metabolite in healthy male volunteers.

Detailed Description

This study consists of Part 1 followed Part 2.

Part 1 (Dose escalation study, SA001 60mg~300mg dose group) The part 1 is a dose escalation study. The starting dose is SA001 60mg, and the maximum dose is 300mg. Each dose group is assigned to SA001 or Placebo in a ratio of 3:1. The pharmacokinetics, safety and tolerability of SA001 and its metabolite are investigated after a single oral administration on the fasting state.

Part 2 (Single dose and food effect study, SA001 120mg and 300mg dose group) The purpose of this part 2 is to evaluate the food effect of a high-fat diets(HFDs) on the single oral dose pharmacokinetics of SA001 and its metabolite.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: QUADRUPLE

Study Groups

Cohort 1 (SA001 60mg or Placebo)

6 subjects receiving a single dose of 60mg SA001 and 2 subjects receiving placebo

Group Type: EXPERIMENTAL

SA001 60mg or Placebo

Intervention Type: DRUG

• Study Drug: SA001 60mg
• Comparator: Placebo
• Cohort 1 in the part 1 (Dose escalation study)

Cohort 2 (SA001 120mg or Placebo)

6 subjects receiving a single dose of 120mg SA001 and 2 subjects receiving placebo

Group Type: EXPERIMENTAL

SA001 120mg or Placebo

Intervention Type: DRUG

• Study Drug: SA001 120mg
• Comparator: Placebo
• Cohort 2 in the part 1 (Dose escalation study) and part 2 (Food effect study)

Cohort 3 (SA001 180mg or Placebo)

6 subjects receiving a single dose of 180mg SA001 and 2 subjects receiving placebo

Group Type: EXPERIMENTAL

SA001 180mg or Placebo

Intervention Type: DRUG

• Study Drug: SA001 180mg
• Comparator: Placebo
• Cohort 3 in the part 1 (Dose escalation study)

Cohort 4 (SA001 240mg or Placebo)

6 subjects receiving a single dose of 240mg SA001 and 2 subjects receiving placebo

Group Type: EXPERIMENTAL

SA001 240mg or Placebo

Intervention Type: DRUG

• Study Drug: SA001 240mg
• Comparator: Placebo
• Cohort 4 in the part 1 (Dose escalation study)

Cohort 5 (SA001 300mg or Placebo)

6 subjects receiving a single dose of 300mg SA001 and 2 subjects receiving placebo

Group Type: EXPERIMENTAL

SA001 300mg or Placebo

Intervention Type: DRUG

• Study Drug: SA001 300mg
• Comparator: Placebo
• Cohort 5 in the part 1(Dose escalation study) and part 2 (Food effect study)

Interventions

SA001 60mg or Placebo

• Study Drug: SA001 60mg
• Comparator: Placebo
• Cohort 1 in the part 1 (Dose escalation study)

Intervention Type: DRUG

SA001 120mg or Placebo

• Study Drug: SA001 120mg
• Comparator: Placebo
• Cohort 2 in the part 1 (Dose escalation study) and part 2 (Food effect study)

Intervention Type: DRUG

SA001 180mg or Placebo

• Study Drug: SA001 180mg
• Comparator: Placebo
• Cohort 3 in the part 1 (Dose escalation study)

Intervention Type: DRUG

SA001 240mg or Placebo

• Study Drug: SA001 240mg
• Comparator: Placebo
• Cohort 4 in the part 1 (Dose escalation study)

Intervention Type: DRUG

SA001 300mg or Placebo

• Study Drug: SA001 300mg
• Comparator: Placebo
• Cohort 5 in the part 1(Dose escalation study) and part 2 (Food effect study)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. 19 years to 45 years (Healthy male Korean)

2. Body weight of 55 to 90kg; and BMI of 18.0 to 27.0 kg/m^2

3. Subject who voluntarily agrees to participate in this study and has given a written informed consent, after fully understanding the detailed explanation of this study

Exclusion Criteria

1. Subject with a disease history of any clinically significant condition as below.

• Liver, Kidney, nervous system, immune system, respiratory system, endocrine system, tumor, cardiovascular disease or mental illness (mood disorder or obsessive-compulsive disorder etc.) etc.

2. Subject with a history of gastrointestinal disease (Crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (except simple appendicectomy or hernia surgery) that may affect the absorption of the study drug

3. Subject with a history of clinically significant hypersensitivity or hypersensitivity reactions to drugs (aspirin, antibiotics, etc.)

4. Serum ALT(SGPT)/AST(SGOT) >1.5×institutional upper limit normal (ULN)

5. eGFR< 90mL/min/1.73m^2

6. Systolic blood pressure <100 mmHg or >160 mmHg

7. Diastolic blood pressure <60 mmHg or >100 mmHg

8. Inadequate cardiac function confirmed by 12-lead ECG findings at screening as followings:

• QTcF > 430msec (males)
• PR interval > 200msec or < 110msec
• QRS complex > 120msec
• Evidence of 2nd- or 3rd-degree atrioventricular (AV) block
• Pathologic Q waves (defined as Q-wave > 40msec or depth > 0.5mV)
• Evidence of ventricular preexicitation, left bundle branch block (LBBB), right bundle branch block (RBBB, Incomplete RBBB)

9. Subject with risk factors for Torsade de pointes such as long QT syndrome, family history of sudden death, heart failure, hypokalemia, and arrhythmias

10. Subject with a history of drug abuse within 60 days prior to screening or who is positive for drugs of abuse in urine tests at screening

11. Subject who received any prescription drug or herbal medicine within 14 days prior to the first administration of the Investigational product

12. Subject who received any drugs such as

• Prescription drug or herbal medicine within 14 days prior to the first administration of the investigational products
• Over the counter (OTC) or vitamin within 7 days prior to the first administration of the investigational products

13. Subject who received other investigational products within 90 days prior to the first administration of the investigational products

14. Subject who continuously drink alcohol (more than 21 units/week, 1 unit = 10 g of pure alcohol) or cannot abstain from alcohol during the study period

15. Subject with history of smoking within 90 days prior to the first administration of the investigational products

16. Subject who cannot prohibit grapefruit/ caffeine-containing foods during the study period from 3 days before the first administration of the investigational products

17. Man of reproductive potential not willing to use contraceptive measures during the study period

18. Subject not eligible for study participation in the opinion of the investigator

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Samjin Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kyung-sang Yu, M.D., Ph.D., M.B.A

Role: PRINCIPAL_INVESTIGATOR

Seoul National University College of Medicine / Seoul National University Hospital

Locations

Seoul National University Hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

SJSA001

Identifier Type: -

Identifier Source: org_study_id